ObsEva SA Shares to Begin Trading on SIX Swiss Exchange

ObsEva SA / ObsEva SA Shares to Begin Trading on SIX Swiss Exchange . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Listing of 45'381'252 registered shares with a par value of 1/13 of CHF 1 per share
   

Anticipated market capitalisation of more than CHF 650 million
 

Trading on SIX Swiss Exchange scheduled for July 13, 2018 under the ticker symbol 'OBSN'.
 

ObsEva has a unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women.
 

ObsEva therapies in development reaching major clinical milestones in 2018 and confirmation of potential therapeutic benefits

Geneva, Switzerland and Boston, MA - July 6, 2018 - ObsEva SA (NASDAQ: OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced the listing of its shares on SIX Swiss Exchange with the publication of its listing prospectus. ObsEva shares are expected to begin trading on the SIX Swiss Exchange on July 13, 2018, under the ticker symbol 'OBSN' under SIX's International Reporting Standard. ObsEva will not issue any new shares in connection with the listing in Switzerland.

The company is already listed on the NASDAQ Global Select Market (OBSV) since January 2017. The trading of ObsEva's shares on NASDAQ will continue in addition to the SIX listing. With listing on SIX Swiss Exchange, ObsEva is expecting to raise its profile among Swiss and European investors, provide another robust market for any future potential financing activities and to secure for its shareholders the protection offered by the Swiss takeover rules.

Ernest Loumaye, CEO and Co-Founder of ObsEva said: "Millions of women worldwide are affected by serious conditions compromising their reproductive health and pregnancy. At ObsEva, we believe the efficacy of the current standard of care is limited and associated with clear safety issues for women. The innovative solutions we are developing can potentially help resolve some of the major obstacles by offering orally active medications with fast onset therapeutic effect and fewer side effects. As a Swiss company, we are honoured to be listed on the SIX Swiss Exchange and to take another important step toward achieving our goals."